Drug Trial Radar · NCT03768505
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
Last checked: Nov 19, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
169
Actual
Start
Jun 25, 2019
Primary completion
Mar 24, 2023
Study completion Mar 24, 2023
Sponsor
- Lead sponsor
- MEI Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the study of the PI3Kδ inhibitor Zandelisib (ME-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy
Conditions
- Follicular Lymphoma (FL)
- Non Hodgkin Lymphoma
- Marginal Zone Lymphoma
Interventions
Zandelisib (ME-401)Drug
Zandelisib (ME-401) 60 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) of ME-401 in Relapsed or Refractory FL or MZLTime frame: 3 years 9 months
Locations
115 sites in 14 countries. Site status is shown where the registry gives one.
Oncology Institute of Hope and Innovation
Tucson, Arizona
Pacific Cancer Medical Center, Inc.
Anaheim, California
Tower Hematology Oncology
Beverly Hills, California
The Oncology Institute of Hope and Innovation
Downey, California
Sharp Memorial Hospital
San Diego, California
H. Lee Moffit Cancer Center
Tampa, Florida
Cleveland Clinic-Florida
Weston, Florida
Rush University Medical Center
Chicago, Illinois
Advocate Health & Hospitals Corporation
Niles, Illinois
Investigative Clinical Research of Indiana LLC
Indianapolis, Indiana
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Medical School
Ann Arbor, Michigan
St. Vincent Frontier Cancer Center
Billings, Montana
The Oncology Institute of Hope and Innovation
Henderson, Nevada
Memorial Sloan Kettering
Basking Ridge, New Jersey
Memorial Sloan Kettering
Middletown, New Jersey
Memorial Sloan Kettering
Montvale, New Jersey
San Juan Oncology
Farmington, New Mexico
Memorial Sloan Kettering
Commack, New York
Memorial Sloan Kettering
Harrison, New York
Clinical Research Alliance
Lake Success, New York
Memorial Sloan Kettering
New York, New York
Stony Brook University
Stony Brook, New York
Memorial Sloan Kettering
Uniondale, New York
Duke Cancer Center
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Vanderbilt University
Nashville, Tennessee
Renovatio Clinical
Houston, Texas
Swedish Cancer Institute
Edmonds, Washington
Swedish Cancer Institute
Seattle, Washington
Medical Oncology Associates PS
Spokane, Washington
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Marshfield Medical Center
Marshfield, Wisconsin
Liverpool Hospital
Sydney, Australia
Peninsula and South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
The Perth Blood Institute
West Perth, Western Australia, Australia
Kepler Universitatsklinikum GmBH
Linz, Austria
Medical University of Vienna
Vienna, Austria
AZ Sint-Jan Brugge-Oostende
Bruges, Belgium
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.